Cassava Sciences (NASDAQ:SAVA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.79, Briefing.com reports. During the same period in the previous year, the company posted ($0.61) earnings per share.
Cassava Sciences Stock Up 6.4 %
NASDAQ:SAVA traded up $1.61 during trading hours on Friday, hitting $26.95. 2,036,051 shares of the company's stock traded hands, compared to its average volume of 1,709,910. Cassava Sciences has a 52 week low of $8.79 and a 52 week high of $42.20. The business's fifty day simple moving average is $27.72 and its two-hundred day simple moving average is $23.02. The firm has a market cap of $1.29 billion, a P/E ratio of -19.11 and a beta of -0.59.
Analysts Set New Price Targets
Several analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $116.00 price target on shares of Cassava Sciences in a research report on Friday. Rodman & Renshaw reissued a "buy" rating and set a $107.00 price objective on shares of Cassava Sciences in a report on Thursday, August 8th.
Get Our Latest Stock Report on SAVA
Cassava Sciences Company Profile
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Recommended Stories
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
